{"id":864954,"date":"2025-06-30T09:48:22","date_gmt":"2025-06-30T13:48:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/"},"modified":"2025-06-30T09:48:22","modified_gmt":"2025-06-30T13:48:22","slug":"abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/","title":{"rendered":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <i>Capstan&#8217;s lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases<\/i>\n        <\/li>\n<li>\n          <i>Proposed acquisition strengthens AbbVie&#8217;s commitment to transforming the future of patient care with Capstan&#8217;s innovative tLNP platform technology<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NORTH CHICAGO, Ill.<\/span> and <span class=\"xn-location\">SAN DIEGO<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 30, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (&#8220;Capstan&#8221;), a clinical-stage biotechnology company dedicated to advancing\u00a0<i>in vivo<\/i>\u00a0engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class <i>in vivo<\/i> tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of B cell-mediated autoimmune diseases. Additionally, AbbVie will acquire Capstan&#8217;s proprietary tLNP platform technology designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types\u00a0<i>in vivo.<\/i><\/p>\n<p>&#8220;Scientific innovation is required to address not just the symptoms of autoimmune diseases, but also to resolve and potentially cure the underlying disease,&#8221; said <span class=\"xn-person\">Roopal Thakkar<\/span>, M.D., executive vice president, research and development and chief scientific officer, AbbVie. &#8220;By advancing CPTX2309 and utilizing Capstan&#8217;s novel platform technology, AbbVie and Capstan aim to transform the care of those living with autoimmune diseases by developing treatments that have the potential to reset the immune system.&#8221;<\/p>\n<p>&#8220;<i>In vivo<\/i> CAR-T represents a potential new treatment modality in medicine \u2013 embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases,&#8221; said\u00a0Laura Shawver, Ph.D., president and chief executive officer, Capstan. &#8220;Through AbbVie&#8217;s world-leading expertise in immunology research, clinical development, and its commercialization capabilities, we believe that this transaction moves us closer to delivering on our shared mission to bring these innovative therapies to patients in need.&#8221;<\/p>\n<p>B cells contribute to the pathogenesis of autoimmune diseases. CD19 is a cell surface receptor expressed on B cells and is a clinically validated target for B cell depletion using <i>ex vivo<\/i> CAR-T cell therapy in autoimmune diseases. CPTX2309, a product of Capstan&#8217;s proprietary technology platform that includes hepatic de-targeting, delivers an mRNA payload encoding an anti-CD19 CAR preferentially to reprogram CD8-expressing cytotoxic T cells. This process is achieved <i>in vivo<\/i>, without the need for lymphodepletion preconditioning and complex <i>ex vivo <\/i>manufacturing. The <i>in vivo<\/i>-modified CD8-expressing T cells will transiently express the CD19 CAR and deplete B cells in the periphery and tissues. Depletion of autoreactive antibody-producing pathogenic memory B cells and repopulation with na\u00efve B cells, resulting in immune reset, has the potential to prevent disease progression and induce clinical remission.<\/p>\n<p>Under the terms of the agreement, AbbVie will pay\u00a0up to <span class=\"xn-money\">$2.1<\/span> billion\u00a0in cash at closing to acquire Capstan, subject to certain customary adjustments. The transaction is subject to the satisfaction of customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.<\/p>\n<p>\n        <b>Advisors<\/b>\n      <\/p>\n<p>Capstan&#8217;s exclusive financial advisor was\u00a0Centerview Partners LLC and Cooley LLP served as legal advisor.<\/p>\n<p>\n        <b>About AbbVie<\/b>\n      <\/p>\n<p>AbbVie&#8217;s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people&#8217;s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care \u2013 and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=1616874572&amp;u=http%3A%2F%2Fwww.abbvie.com%2F&amp;a=www.abbvie.com\" target=\"_blank\" rel=\"nofollow\">www.abbvie.com<\/a>. Follow @abbvie on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=197974556&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&amp;a=LinkedIn%2C\" target=\"_blank\" rel=\"nofollow\">LinkedIn,<\/a>\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=1794031742&amp;u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=919175768&amp;u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&amp;a=Instagram\" target=\"_blank\" rel=\"nofollow\">Instagram<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=1312206334&amp;u=https%3A%2F%2Ftwitter.com%2Fabbvie&amp;a=X+(formerly+Twitter)\" target=\"_blank\" rel=\"nofollow\">X (formerly Twitter)<\/a>\u00a0and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=3630345233&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&amp;a=YouTube.\" target=\"_blank\" rel=\"nofollow\">YouTube.<\/a><\/p>\n<p>\n        <b>About Capstan Therapeutics, Inc<\/b><br \/>\n        <b>.<\/b>\u00a0<\/p>\n<p>Capstan is a clinical-stage biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted <i>in vivo<\/i>\u00a0RNA technologies. Our proprietary CellSeeker\u2122 tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, that deliver an RNA payload capable of engineering cells\u00a0<i>in vivo<\/i>. Capstan&#8217;s initial focus is on developing\u00a0<i>in vivo\u00a0<\/i>CAR-T therapies designed to combine the potency of CAR-T therapy with the convenience of an off-the-shelf product for the treatment of autoimmune diseases. \u00a0For more information, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=831693021&amp;u=http%3A%2F%2Fwww.capstantx.com%2F&amp;a=www.capstantx.com\" target=\"_blank\" rel=\"nofollow\">www.capstantx.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4459334-1&amp;h=3318217087&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcapstan-therapeutics%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>No Offer or Solicitation<\/b>\n      <\/p>\n<p>This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\u00a0<\/p>\n<p>\n        <i>Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project&#8221; and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; of AbbVie&#8217;s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.<\/i>\n      <\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>AbbVie Contacts\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Media:\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Lindsay Cangemi<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:lindsay.cangemi@abbvie.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">lindsay.cangemi@abbvie.com<\/a> \u00a0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investors:\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Liz Shea\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:liz.shea@abbvie.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">liz.shea@abbvie.com<\/a>\u00a0<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Capstan Contacts\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Media:\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Rhiannon Benilov <br \/><a href=\"mailto:capstan@tenbridgecommunications.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">capstan@tenbridgecommunications.com<\/a>\u00a0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investors:\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Miguel Arcinas\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <a href=\"mailto:ir@capstantx.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">ir@capstantx.com<\/a>\u00a0<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder5947\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg\" title=\"AbbVie logo\" alt=\"AbbVie logo\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG20890&amp;sd=2025-06-30\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology-302494390.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology-302494390.html<\/a><\/p>\n<p>SOURCE  AbbVie<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG20890&amp;Transmission_Id=202506300831PR_NEWS_USPR_____CG20890&amp;DateId=20250630\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Capstan&#8217;s lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie&#8217;s commitment to transforming the future of patient care with Capstan&#8217;s innovative tLNP platform technology NORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 \/PRNewswire\/ &#8212;\u00a0AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (&#8220;Capstan&#8221;), a clinical-stage biotechnology company dedicated to advancing\u00a0in vivo\u00a0engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-864954","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Capstan&#8217;s lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie&#8217;s commitment to transforming the future of patient care with Capstan&#8217;s innovative tLNP platform technology NORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 \/PRNewswire\/ &#8212;\u00a0AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (&#8220;Capstan&#8221;), a clinical-stage biotechnology company dedicated to advancing\u00a0in vivo\u00a0engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, &hellip; Continue reading &quot;AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-30T13:48:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology\",\"datePublished\":\"2025-06-30T13:48:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/\"},\"wordCount\":1091,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/\",\"name\":\"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"datePublished\":\"2025-06-30T13:48:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/386913\\\/AbbVie_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk","og_description":"PR Newswire Capstan&#8217;s lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie&#8217;s commitment to transforming the future of patient care with Capstan&#8217;s innovative tLNP platform technology NORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 \/PRNewswire\/ &#8212;\u00a0AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (&#8220;Capstan&#8221;), a clinical-stage biotechnology company dedicated to advancing\u00a0in vivo\u00a0engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, &hellip; Continue reading \"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-30T13:48:22+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology","datePublished":"2025-06-30T13:48:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/"},"wordCount":1091,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/","name":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","datePublished":"2025-06-30T13:48:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/386913\/AbbVie_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/864954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=864954"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/864954\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=864954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=864954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=864954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}